Cervical Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Cervical Cancer is a $819K market dominated by a single asset (TIVDAK) in peak lifecycle stage.
Key Trends
- Extreme market concentration: one product (TIVDAK) represents 86% of spending
- Limited commercial footprint: only 2 products with quantified spending; 5 of 7 products lack revenue data
- Active pipeline with 378 trials across multiple phases, suggesting future competitive pressure
Career Verdict
This is a niche, high-risk specialization with limited near-term growth but potential upside if pipeline candidates succeed.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | TIVDAK (TISOTUMAB VEDOTIN) | Pfizer | $704K | 86% | PEAK | Stable | |
| 2 | ZYCLARA (IMIQUIMOD) | Bausch + Lomb | $115K | 14% | PEAK | Stable | 4.0yr |
Drug Class Breakdown
market-defining
patent cliff pending 2030
Career Outlook
StableCervical cancer is a therapeutically validated but commercially modest market with intense concentration in a single Pfizer asset. The field offers stable, specialized roles but limited near-term growth; career advancement depends on pipeline success or cross-indication opportunities. This is a specialist track best suited for candidates with strong oncology foundations seeking deep disease expertise rather than rapid advancement.
Breaking In
Enter through a large oncology player (Pfizer, Novartis, AstraZeneca) with a commercial or R&D role in oncology broadly, then specialize in cervical cancer to build deep expertise.
For Experienced Professionals
Experienced oncology professionals should evaluate whether pipeline catalysts justify staying in this niche or lateral-moving to higher-growth indications; consider roles in medical affairs or market access if targeting long-term stability.
In-Demand Skills
Best For
Hiring Landscape
5,302 jobs are available across oncology-focused companies, but only a fraction target cervical cancer specialists. Pfizer and Novartis are primary employers with 542 and 622 jobs respectively (company-wide oncology roles). Commercial departments dominate hiring (1,077 jobs) at an average salary of $257K, reflecting need for field-level expertise.
Top Hiring Companies
By Department
Cervical cancer specialists will find jobs primarily in commercial and R&D roles at larger oncology-focused organizations, with commercial positions commanding premium salaries.
On Market (1)
Approved therapies currently available
Competitive Landscape
57 companies ranked by most advanced pipeline stage
+27 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 211,750 patients across 50 trials
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury
CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Trial to Optimally Show the Pharmacological Action of Z-100
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer
Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Online Adaptive Radiotherapy for Cervical Cancer
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer
Related Jobs in Oncology
US Regional Director of Medical Affairs GYN Malignancies
US Regional Director of Medical Affairs GYN Malignancies
Senior IT Infrastructure Engineer
Clinical Data Associate
Vice President and Head of Business Development
Associate Scientist (BS/MS) contractor – Lentiviral Vector Research & Early Process Development (100% Bench)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.